Ingrezza

Active Ingredient(s): Valbenazine
FDA Approved: * April 11, 2017
Pharm Company: * NEUROCRINE BIOSCIENCES INC
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ingrezza Overview

Valbenazine, sold under the trade name Ingrezza, is a medication use to treat tardive dyskinesia.[1] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.[2] Contents 1 Medical use 2 Contraindications 3 Adverse effects 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 Society and culture 5.1 Commercial aspects 5.2 Intellectual property 5.3 Names 6 Research 7 References Medical use Valbenazine is used to treat tardive dyskinesia in adults.[1] Contrai...

Read more Ingrezza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Valbenazine

Recent Ingrezza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Valbenazine
  • Capsule: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ingrezza: (1 result)

Sorted by National Drug Code
  • 70370-1040 Ingrezza 40 mg Oral Capsule by Neurocrine Biosciences, Inc.

Other drugs which contain Valbenazine or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 24 August 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.